Consun Pharmaceutical Group (1681) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 rose 23.7% year-over-year to RMB1,568.6 million, driven by strong growth across major product lines, especially kidney and gynaecology/paediatric medicines.

• Net profit attributable to equity shareholders increased 24.6% year-over-year to RMB498.3 million, with basic EPS up 18.0% to RMB0.59.

• Gross profit margin improved to 77.1%, up 2.4 percentage points from the prior year, mainly due to lower raw material costs.

• Interim dividend of HKD0.33 per share declared for the period, to be paid in September 2025.

Financial highlights

• Gross profit reached RMB1,208.7 million, up 27.6% year-over-year.

• Net cash from operating activities grew 40.6% to RMB492.7 million.

• Finance costs dropped 81.5% to RMB2.5 million due to reduced loan scale and lower interest rates.

• Distribution costs increased 25.2% to RMB515.7 million; administrative expenses rose 31.8% to RMB177.6 million.

• Other income declined 36.6% to RMB23.6 million, mainly due to reduced government grants and higher exchange losses.

Outlook and guidance

• Management aims to surpass annual performance targets by optimizing resource allocation, strengthening execution, and enhancing operational efficiency in the second half of 2025.

• Focus remains on high-quality development and overcoming industry challenges such as integration, procurement expansion, and raw material price fluctuations.